D. Inflammatory Bowel Disease

The FDA approved the subcutaneous formulation of Celltrion USA’s Zymfentra as maintenance therapy for patients with moderately-to-severely active ulcerative colitis and Crohn’s disease following induction with IV administered infliximab.

Artificial intelligence has been making waves, especially with ChatGPT, and it is poised to remarkably change the way physicians practice medicine; however, they should be cautious of its use as it will not replace their expertise.

In a Healio video exclusive, Edward V. Loftus Jr., MD, highlighted the growing recognition that diet, specifically tailored nutrition interventions, can play a crucial role in the management of several gastrointestinal disorders.

Gastroenterology had a big year in 2022, with potentially game-changing FDA approvals for inflammatory bowel disease and several first-in-class therapies, yet the FDA’s rejection of the first hepatitis D therapy still looms large.

The FDA has agreed on Abivax’s initial pediatric study plan for the development of obefazimod in children aged 2 to 17 years with inflammatory bowel disease, the company announced in a press release.

A combination of viruses has been linked to an unexplained surge of severe hepatitis in children.

Anti-tumor necrosis factor therapy had reduced efficacy and safety for bio-naive patients with older-onset inflammatory bowel disease compared with younger patients, according to a study published in Scientific Reports.

Biopharmaceutical company AbbVie announced FDA approval for Rinvoq for the treatment of adults with moderately to severely active ulcerative colitis.

In this Healio video series, which focuses on cultural competency in the treatment of inflammatory bowel disease, patient advocate Madhura Balasubramaniam shares her experience living with Crohn’s disease in India.